Divi's Laboratories Limited has informed the Exchange about appointment of Secretarial Auditors.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Divi's Laboratories reported audited standalone revenue from operations of ₹9,198 cr in FY25 vs ₹7,665 cr in FY24 (~20% growth), with standalone PAT rising to ₹2,209 cr from ₹1,576 cr (~40% growth). Consolidated revenue was ₹9,360 cr and consolidated PAT was ₹2,191 cr. The Board recommended a final dividend of ₹30/- per share (1500%) on a face value of ₹2, subject to shareholder approval. CFO Mr. L. Kishore Babu will superannounce on August 1, 2025, and Mr. Venkatesa Perumallu Pasumarthy (currently GM-Finance, a CA with 37+ years' experience) will take over as CFO from the same date. M/s. V. Bhaskara Rao & Co. was appointed as Secretarial Auditor for five years (FY26–FY30). Statutory auditor Price Waterhouse issued an unmodified opinion on both standalone and consolidated results. Operating cash flow was healthy at ₹1,650 cr (standalone).
Strong double-digit earnings growth and a generous 1500% dividend are positive for shareholders. Smooth, internally-planned CFO transition and a clean audit opinion reinforce governance confidence, while the planned succession removes near-term leadership uncertainty.